4-(5-甲基-1,2,4-噁二唑)苯胺 | 10185-68-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: 4-(5-甲基-1,2,4-噁二唑)苯胺
• 中文别名: 4-(5-甲基-1,2,4-恶二唑-3-基)苯胺；4-(5-甲基-1,2,4-恶-3-基)苯胺
• 英文名称: 4-(5-methyl-1,2,4-oxadiazol-3-yl)-aniline
• 英文别名: 4-(5-Methyl-1,2,4-oxadiazol-3-yl)aniline
• CAS: 10185-68-9
• 化学式: C₉H₉N₃O
• 分子量: 175.19
• InChiKey: GXOWTIUKDYSZKJ-UHFFFAOYSA-N

物化性质

• 熔点：
  113 °C

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.11
• 拓扑面积：
  64.9
• 氢给体数：
  1
• 氢受体数：
  4

安全信息

• 危险品标志：
  Xi
• 海关编码：
  2934999090

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 4-(5-methyl-1,2,4-oxadiazol-3-yl)aniline
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 4-(5-methyl-1,2,4-oxadiazol-3-yl)aniline
CAS number: 10185-68-9

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, refrigerated.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C9H9N3O
Molecular weight: 175.2

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  4-(5-甲基-1,2,4-噁二唑)苯胺 在 N-甲基吗啉 作用下， 以 甲醇 、 二氯甲烷 为溶剂， 反应 12.0h， 生成 N¹,N⁶-dimethyl-N¹,N⁶-bis[4-(5-methyl-1,2,4-oxadiazol-3-yl)phenyl]hexanediamide
  参考文献：
  名称：

  高活性抗肺孢子菌双苯甲脒的开发：深入了解所选取代基对体外活性的影响

  摘要：

  在这里，我们描述了 21 种喷他脒类似物在 ATP 生物发光测定中对抗真菌病原体卡氏肺囊虫的效力，并在 2 种哺乳动物细胞系中进行了毒性分析。将两个 5-甲基-1,2,4-恶二唑环的还原应用于酸不稳定双脒的合成。根据喷他脒先导结构的主要结构变化，在 3 组化合物的背景下讨论了抗肺孢子虫活性。这些组包括：1) 1,4-双(亚甲基)哌嗪衍生物1-5；2）链烷二酰胺衍生物6-10；3) 烷烃衍生的双苯甲脒 11-21。18种化合物的IC50值低于喷他脒的IC50。四种双脒在纳克浓度下具有活性。在烷桥中引入硫原子、用咪唑啉环取代脒基、或者将硝基或氨基连接到苯环上，是新的主要结构具有显着活性的原因。绝大多数化合物，包括四种高活性化合物，可归类为对宿主细胞温和或无毒的化合物。这些化合物有望成为新型抗肺孢子菌药物的候选者。

  DOI：

  10.1039/c7md00445a
• 作为产物：
  描述：

  5-甲基-3-(4-硝基苯基)-1,2,4-恶二唑 生成 4-(5-甲基-1,2,4-噁二唑)苯胺
  参考文献：
  名称：

  PHARMACEUTICAL INTERMEDIATES AND PROCESS FOR THE PREPARATION THEREOF

  摘要：

  本发明涉及一种制备式为或其药学上可接受的盐的达比加群酯的方法。

  公开号：

  US20140155614A1
• 作为试剂：
  描述：

  4-(5-甲基-1,2,4-噁二唑)苯胺 、 4-Fluoro-7-methoxy-2,3-dihydrobenzofuran-5-carbaldehyde 、 三甲基氰硅烷 、 三氟甲烷磺酸镱水合物 在 4-(5-甲基-1,2,4-噁二唑)苯胺 、 氮气 、 乙酸乙酯 、 crude product 作用下， 以 四氢呋喃 为溶剂， 反应 16.0h， 以to give (4-fluoro-7-methoxy-2,3-dihydrobenzofuran-5-yl)-[4-(5-methyl-[1,2,4]oxadiazol-3-yl)phenylamino]acetonitrile (crude product)的产率得到(4-Fluoro-7-methoxy-2,3-dihydrobenzofuran-5-yl)-[4-(5-methyl-[1,2,4]oxadiazol-3-yl)phenylamino]acetonitrile
  参考文献：
  名称：

  Triazolone derivatives

  摘要：

  化合物的一般式如下（1）：其中R1a、R1b、R1c和R1d分别独立地表示氢等；R2表示可选取代的苯基等；R3表示可选取代的C6-10芳基等；Z1和Z2分别独立地表示氢或其盐或其水合物。

  公开号：

  US07928228B2

文献信息

• 4-(Benzoimidazol-2-yl)-thiazole Compounds and Related Aza Derivatives
  申请人：Actelion Pharmaceuticals Ltd.

  公开号：US20140371204A1

  公开（公告）日：2014-12-18

  The invention relates to compounds of Formula (I) wherein ring A, X, (R 1 ) n , R 2 , R 3 , R 4 , R 4′ , R 5 , n, and p are as described in the description; to pharmaceutically acceptable salts thereof, and to the use of such compounds as medicaments, especially as modulators of the CXCR3 receptor.

  本发明涉及式(I)化合物，其中环A、X、(R1)n、R2、R3、R4、R4′、R5、n和p如描述中所述；涉及药用可接受的盐，以及将此类化合物用作药物，尤其是用作CXCR3受体的调节剂。
• Heterocyclic compounds as inhibitors of factor VIIa
  申请人：Glunz W. Peter

  公开号：US20060211720A1

  公开（公告）日：2006-09-21

  The present invention relates generally to compounds that inhibit serine proteases. In particular it is directed to novel heterocyclic compounds, or a stereoisomer or pharmaceutically acceptable salt, solvate, or prodrug form thereof, which are useful as selective inhibitors of serine protease enzymes of the coagulation cascade; for example thrombin, factor VIIa, factor Xa, factor XIa, factor IXa, and/or plasma kallikrein. In particular, it relates to compounds that are factor VIIa inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds and methods of using the same.

  本发明一般涉及抑制丝氨酸蛋白酶的化合物。具体而言，它涉及新颖的杂环化合物，或其立体异构体或药用可接受的盐、溶剂合物或前药形式，这些化合物可用作凝血级联中丝氨酸蛋白酶的选择性抑制剂；例如凝血酶、第VIIa因子、第Xa因子、第XIa因子、第IXa因子和/或血浆激肽。具体而言，它涉及第VIIa因子抑制剂的化合物。本发明还涉及包含这些化合物的药物组合物以及使用它们的方法。
• [EN] 4-(BENZOIMIDAZOL-2-YL)-THIAZOLE COMPOUNDS AND RELATED AZA DERIVATIVES<br/>[FR] COMPOSÉS DE 4-(BENZOIMIDAZOL-2-YLE)-THIAZOLE ET DÉRIVÉS AZA ASSOCIÉS
  申请人：ACTELION PHARMACEUTICALS LTD

  公开号：WO2013114332A1

  公开（公告）日：2013-08-08

  The invention relates to compounds of Formula (I) wherein ring A, X, (R1)n, R2, R3, R4, R4', R5, n, and p are as described in the description; to pharmaceutically acceptable salts thereof, and to the use of such compounds as medicaments, especially as modulators of the CXCR3 receptor.

  本发明涉及式(I)化合物，其中环A、X、(R1)n、R2、R3、R4、R4'、R5、n和p如描述中所述；涉及药用可接受的盐，以及将此类化合物用作药物，尤其是用作CXCR3受体的调节剂。
• The first one-pot ambient-temperature synthesis of 1,2,4-oxadiazoles from amidoximes and carboxylic acid esters
  作者：Sergey Baykov、Tatyana Sharonova、Anton Shetnev、Sergey Rozhkov、Stanislav Kalinin、Alexey V. Smirnov

  DOI：10.1016/j.tet.2017.01.007

  日期：2017.2

  The first one-pot room-temperature protocol for the synthesis of 3,5-disubstituted-1,2,4-oxadiazoles via the condensation between amidoximes and carboxylic acid esters in superbase medium MOH/DMSO is reported. A broad spectrum of alkyl, aryl and hetaryl amidoximes and esters was examined. This reaction route provides convenient access to 1,2,4-oxadiazoles, which is highly desirable because in the light

  据报道，第一个单锅室温规程是通过在超碱性介质MOH / DMSO中通过a肟和羧酸酯之间的缩合反应合成3,5-二取代-1,2,4-恶二唑。检查了烷基，芳基和杂芳基肟和酯的广谱光谱。该反应途径提供了方便地获得1,2,4-恶二唑的途径，这是非常需要的，因为鉴于这种特权支架，公认其是新型治疗剂和高科技材料设计的重要核心。
• [EN] PROCESS FOR THE MANUFACTURE OF DABIGATRAN ETEXILATE AND INTERMEDIATES THEREOF<br/>[FR] PROCÉDÉ DE FABRICATION D'ÉTÉXILATE DE DABIGATRAN ET DE SES INTERMÉDIAIRES
  申请人：EGIS GYOGYSZERGYAR NYILVANOSAN MUEKOEDOE RESZVENYTARSASAG

  公开号：WO2012153158A1

  公开（公告）日：2012-11-15

  The present invention relates to a process for the preparation of dabigatran etexilate of the formula (1) or the pharmaceutically accepted salts thereof.

  本发明涉及一种制备化合物达比加群酯（Dabigatran Etexilate）及其药用盐的方法。